 |
|
|
| |
Treatment-Emergent Integrase Strand Transfer Inhibitor (INSTI) Resistance-Associated Mutations Among People Living With HIV-1 Treated With Dolutegravir (DTG) + Lamivudine (3TC) With Pre-existing M184V/I From Real-world and Interventional Studies
|
| |
| |
HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, Scotland
Dainielle Fox,1 Gary Blick,2 Thibault Mesplède,3 Gustavo Verdier,4 Mónica Calderón,1 Chris M. Parry,5 Richard Grove,6 Emilio Letang,7 Julie Priest,1 Bryn Jones5
1ViiV Healthcare, Durham, NC, USA; 2Health Care Advocates International, Stratford, CT, USA; 3Erasmus University Medical Center, Rotterdam, Netherlands; 4ViiV Healthcare, Montréal, Québec, Canada; 5ViiV Healthcare, London, UK; 6GSK, London, UK; 7ViiV Healthcare, Madrid, Spain
|
| |
|
|
|
|
|
